Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About LianBio

LianBio (NASDAQ: LIAN) is a Chinese company focused on bringing paradigm-shifting medicines to patients through partnerships that provide access to science-driven therapeutic discoveries.

LianBio Headquarter Location

9th Floor, Kerry Parkside, 1155 Fangdian Road Unit 901-902

Shanghai, Shanghai, 201204,


Latest LianBio News

New Stocks to Watch at Investor Ideas: (Nasdaq: BFRI) (Nasdaq: CGTX) (Nasdaq: EXAI) (CSE: PBF) (CSE: STGX) (CSE: MJEM)

Jan 14, 2022

New Stocks to Watch at Investor Ideas: (Nasdaq: BFRI) (Nasdaq: CGTX) (Nasdaq: EXAI) (CSE: PBF) (CSE: STGX) (CSE: MJEM)   Point Roberts, WA and Delta, BC - January 14, 2022 ( Newswire) , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining, Plant-Based and Tech. Today's stocks have been added to our lists of free stock directories in each sector. The newest biotech companies are involved in treatments of dermatological conditions, CNS and cancer among other diseases. The latest mining company is focused on cobalt and 'green metals', while the newest plant-based company offers a vegan meat alternative derived from hemp. The newest tech company is a social media company for Generation Z's. Biofrontera Inc. ( Nasdaq: BFRI ) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. COGNITION THERAPEUTICS INC ( Nasdaq: CGTX ) is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Exscientia Ltd. ( Nasdaq: EXAI ) is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka IO Biotech, Inc . ( Nasdaq: IOBT ) is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, in clinical studies and its other pipeline candidates through clinical and preclinical development. IO Biotech is headquartered in Copenhagen, Denmark, and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire). LianBio ( NasdaqGM:LIAN ) is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. MiNK Therapeutics, Inc. ( Nasdaq: INKT ) is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Pyxis Oncology, Inc . ( Nasdaq PYXS ) is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Theseus Pharmaceuticals, Inc. ( Nasdaq:THRX ) is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). Vaxxinity, Inc. ( NasdaqGM:VAXX ) is purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. StrategX Elements Corp . ( CSE:STGX ) is an exploration company poised to be a significant contributor in the green energy sector and emerging low carbon economy. The Company is currently focused on discovery of cobalt and associated 'green' metals in northern Canada. The Company's property portfolio includes two new regional plays: Project 939 & EA South situated near the shores of the East Arm of the Great Slave Lake, Northwest Territories, and Project M on the Melville peninsula, Nunavut, also located close to tidewater. Planet Based Foods Global Inc. ( CSE:PBF ) is focused on producing natural, low processed and nutritional choices that are better for people and the planet. The Company currently offers a high quality, cost-efficient vegan meat alternative derived from hemp proteins including burgers, breakfast sausages, burger crumbles and sausage crumbles.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing LianBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LianBio is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

LianBio Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LianBio Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.